Intermediate-dose prophylaxis significantly reduces annual bleeding rates (ABR and AjBR) and enhances patients' quality of life compared with reactive treatment.

While initial costs increase, prophylaxis becomes increasingly cost effective over time due to the prevention of bleeding episodes.

Pediatric patients may benefit even more from prophylaxis, with potentially lower costs per bleeding event prevented and better long-term outcomes.